Skip to main content
    C

    Crispr Therapeutics AG (CRSP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $40.37
    -1.87 (-4.43%)

    Market Cap: $4.10B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Crispr Therapeutics AG (CRSP) Financials: Revenue, Profit and Cash Flow

    Updated Nov 2, 2026. Financial statements from company filings, amounts in US dollars.

    Crispr Therapeutics AG reported revenue of $3.51M for the fiscal year ended Dec 31, 2025, down 90.6% from the year before. That year, net income was -$581.60M with a net margin of -16569.8%, operating cash flow was -$345.01M and free cash flow was -$345.93M. The quarter ended Sep 30, 2026 had revenue of $12.67M and net income of -$111.44M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue fell from $5.16M, a compound annual decline of 4.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$3.51M-90.6%100.0%-18933.6%-16569.8%
    Dec 2024$37.31M-89.9%100.0%-1250.4%-981.5%
    Dec 2023$371.21M+30885.5%100.0%-60.0%-41.4%
    Dec 2022$1.20M-99.9%100.0%-56190.4%-54271.7%
    Dec 2021$914.96M+127154.9%100.0%40.8%41.3%
    Dec 2020$719.00K-99.8%100.0%-49295.5%-48520.9%
    Dec 2019$289.59M+9169.8%100.0%16.1%23.1%
    Dec 2018$3.12M-92.4%100.0%-5087.8%-5281.1%
    Dec 2017$41.00M+693.9%100.0%-157.7%-166.7%
    Dec 2016$5.16MN/A100.0%-1319.3%-449.3%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$3.51M$37.31M$371.21M$1.20M$914.96M$719.00K$289.59M$3.12M$41.00M$5.16M
    Gross profit$3.51M$37.31M$371.21M$1.20M$914.96M$719.00K$289.59M$3.12M$41.00M$5.16M
    Research and development$381.06M$310.24M$387.33M$461.64M$340.57M$221.38M$179.36M$113.77M$69.80M$42.24M
    Operating income-$664.57M-$466.57M-$222.54M-$673.16M$373.53M-$354.44M$46.74M-$158.94M-$64.65M-$68.13M
    Net income-$581.60M-$366.25M-$153.61M-$650.17M$377.66M-$348.87M$66.86M-$164.98M-$68.36M-$23.20M
    EBITDA-$558.49M-$343.41M-$130.88M-$626.33M$397.48M-$338.87M$77.50M-$156.63M-$61.82M$11.31M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$12.67M$10.18M$1.46M$864.00K$889.00K$892.00K$865.00K$35.69M$602.00K$517.00K$504.00K$201.21M
    Gross profit$12.67M$10.18M$1.46M$864.00K$889.00K$892.00K$865.00K$35.69M$602.00K$517.00K$504.00K$201.21M
    Operating income-$130.04M-$117.27M-$130.25M-$154.76M-$132.06M-$229.32M-$148.42M-$64.59M-$110.13M-$151.26M-$140.59M$69.58M
    Net income-$111.44M-$91.15M-$122.93M-$130.61M-$106.44M-$208.55M-$136.00M-$37.31M-$85.94M-$126.41M-$116.59M$89.35M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $18.58M by $328.98M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$2.27B$2.24B$2.23B$2.24B$2.75B$1.83B$1.07B$489.02M$271.35M$344.96M
    Current assets$1.99B$1.94B$1.91B$1.85B$2.42B$1.72B$987.55M$466.39M$248.38M$320.19M
    Cash and equivalents$347.56M$298.26M$389.48M$211.88M$923.03M$1.17B$943.77M$456.65M$239.76M$315.52M
    Total liabilities$343.43M$309.95M$346.77M$367.58M$352.42M$163.73M$127.33M$96.82M$83.51M$112.12M
    Short-term debt$18.58M$17.29M$15.63M$15.84M$12.16M$11.36M$8.49M$35.32M$44.19M$60.28M
    Shareholder equity$1.92B$1.93B$1.88B$1.88B$2.40B$1.66B$939.42M$392.19M$187.83M$232.85M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$2.56B$2.65B$2.73B$2.27B$2.25B$2.03B$2.17B$2.24B$2.26B$2.34B$2.44B$2.23B
    Total liabilities$908.34M$904.22M$911.26M$343.43M$329.33M$318.59M$336.94M$309.95M$316.47M$358.90M$355.08M$346.77M
    Cash and equivalents$192.03M$291.34M$423.31M$355.19M$286.50M$193.62M$235.18M$298.26M$225.67M$484.47M$707.43M$389.48M
    Shareholder equity$1.65B$1.75B$1.81B$1.92B$1.92B$1.71B$1.83B$1.93B$1.94B$1.98B$2.08B$1.88B
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$345.01M-$142.77M-$260.38M-$495.74M$538.97M-$238.37M$56.68M-$96.24M-$70.09M-$52.86M
    Capital expenditures$914.00K$1.90M$9.47M$37.19M$81.70M$18.36M$6.68M$2.77M$7.81M$3.02M
    Free cash flow-$345.93M-$144.68M-$269.85M-$532.93M$457.27M-$256.72M$49.99M-$99.01M-$77.91M-$55.88M
    Share repurchasesN/AN/AN/AN/AN/AN/AN/AN/AN/A$1.81M
    Investing cash flow-$31.80M-$280.48M$374.65M-$258.65M-$1.04B-$541.17M$1.32M-$2.77M-$8.31M$31.88M
    Financing cash flow$426.03M$331.98M$62.66M$38.59M$250.94M$1.02B$430.98M$315.93M$2.61M$183.22M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$89.68M-$83.50M-$108.90M-$92.55M-$84.63M-$113.88M-$53.95M-$50.03M-$106.91M-$95.58M$109.75M-$96.07M
    Capital expenditures$414.00K$648.00K$504.00K$517.00K$74.00K$117.00K$206.00K$254.00K$219.00K$707.00K$721.00K$738.00K
    Free cash flow-$90.10M-$84.15M-$109.40M-$93.07M-$84.71M-$114.00M-$54.15M-$50.28M-$107.13M-$96.29M$109.03M-$96.81M
    Last 12 quarters

    Frequently Asked Questions About CRSP

    What is Crispr Therapeutics AG's annual revenue?

    Crispr Therapeutics AG reported revenue of $3.51M for the fiscal year ended Dec 31, 2025.

    How fast is Crispr Therapeutics AG's revenue growing?

    Revenue was down 90.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 43.1%.

    Is Crispr Therapeutics AG profitable?

    No. Crispr Therapeutics AG reported net income of -$581.60M for the fiscal year ended Dec 31, 2025, with a net margin of -16569.8%.

    How much free cash flow does CRSP generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$345.01M minus capital expenditures of $914.00K produced free cash flow of -$345.93M.

    How much debt does Crispr Therapeutics AG have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $18.58M and cash and equivalents of $347.56M.